Key result
Tiodazosin reduces mean BP in ~70% of essential hypertension patients but causes notable side effects.
Why the study?
The long-term hemodynamic and systemic effects of tiodazosin in patients with essential hypertension were evaluated due to its structural similarity to prazosin and unique vasodilator properties.
Does tiodazosin improve hemodynamics and lower blood pressure in patients with essential hypertension?
Does tiodazosin improve hemodynamics and lower blood pressure in patients with essential hypertension?
Tiodazosin lowers blood pressure in most patients with essential hypertension but has significant side effects and offers little advantage over existing therapies.
Answers are grounded in this paper and cite their sources.
May warrant caution due to side effects; case-report data leave open any advantage over established agents in essential hypertension.
Tiodazosin, a new antihypertensive, resembles prazosin in structure and alpha-adrenergic-blocking activity, and it also exerts a direct vasodilator effect. We evaluated its long-term hemodynamic and systemic effects in patients with essential hypertension. Our data show that after 10 wk of therapy with tiodazosin, 7 of our 10 patients had significant reduction in intra-arterial mean blood pressure as a result of a fall in systemic vascular resistance. Heart rate, cardiac output, and plasma volume did not change. Systemic effects were minor and included a gain in weight and a reduction in hemoglobin, hematocrit, platelet count, serum protein, albumin, bilirubin, and specific gravity of urine. No patient initially developed orthostatic symptoms after the first dose, but there were transient episodes of light-headedness in three patients, palpitations in two, increased urinary frequency in one, and drooping of eyelid in another during the trial period. One patient developed profound orthostatic hypotension, which could be attributed to the drug. Because of such side effects and the failure to lower blood pressure in 30% of patients with essential hypertension, tiodazosin appears to have several important drawbacks and little advantage over currently available antihypertensives.
No takes yet. Share an insight, caveat, or question.
Vardan et al. (1983) studied essential hypertension (n=10). Tiodazosin was evaluated on significant reduction in intra-arterial mean blood pressure. Tiodazosin therapy for 10 weeks reduced intra-arterial mean blood pressure in 70% of patients with essential hypertension, but caused notable side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: